We demonstrated that β-ARs were highly expressed in both ovarian and cervical cancer cell lines that we tested, providing the rationale for using the non-selective β-ARs antagonist propranolol to counteract the NE-dependent pro-survival stimuli and to enhance the response to trabectedin. The gene discussed is CTBP1; the disease is cervical cancer.